UP FRONT
ASH Directions
ASH Introduces New
Educational Series
The ASH Impact Series is the
Society’s newest educational
offering, which provides free,
on-demand content on key
topics presented at the latest
ASH annual meeting. These
videos can be found on ASH’s
YouTube channel at youtube.
com/user/ASHWebmaster, and
at ASH On Demand (ashondemand.org). They are based on
presentations given at the 2015
ASH Annual Meeting.
In one video, titled “HLH in
Adults,” Nancy Berliner, MD,
ASH Webinars
discusses the diagnosis and treatment of hemophagocytic lymphohistiocytosis (HLH) in adults,
as well as the overall state of our
knowledge of HLH.
In another video with content
stemming from the 2015 annual
meeting, Marcel Van den Brink,
MD, PhD, examines ways of improving thymus function, based
on the session titled “Immunological Ctrl-Alt-Del: Stem Cell
Transplantation for Hematological Malignancies.”
• Consultative hematology
• Thrombosis and hemostasis
• Anemia, iron physiology, and
iron disorders
• Myeloid diseases
• Lymphoid disorders
ASH/FDA Update on Daratumumab
This webinar will discuss the FDA’s accelerated approval of
daratumumab to treat patients with multiple myeloma who
have received at least three prior treatments. Daratumumab is
the first monoclonal antibody approved for treating multiple
myeloma.
Date: Friday, June 17, 2016
Time: 2:30 p.m. Eastern Time
Duration: 1 hour
Presenter Information:
• Mikkael Sekeres, MD, MS, Cleveland Clinic Taussig Cancer
Institute, Cleveland, OH (Moderator)
• Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA
To enable hematologists to stay current with the latest advances in the
rapidly evolving disciplines of adult and pediatric hematology, including
benign and malignant disorders, the ASH Self-Assessment Program (ASH®SAP), Sixth Edition, now contains 23 peer-reviewed chapters, covering
the full spectrum of hematology, including:
This latest edition features 3D
animation and audio, 285 new
questions in the question-andanswer book, and six separate
tests that can be taken individually or together, which are worth
up to 70 continuing medical
education (CME) and American Board of Internal Medicine
(ABIM) Maintenance of Certification (MOC) points.
UPCOMING WEBINARS
• Nicole Gormley, MD, U.S. Food and Drug Administration, Silver
Spring, MD
ASH Self-Assessment Program, Sixth Edition,
Now Available
• Laboratory hematology and
cellular therapy
ASH regularly hosts educational webinars that
feature presentations by experts in the field,
cover current information on how to best diagnose and care for patients, and provide time for
speakers and participants to discuss relevant
issues during a question-and-answer session.
Register at www.hematology.org/Webinar617.
ASH/FDA Update on Ixazomib
This webinar will discuss the FDA approval of ixazomib in combination with two other therapies to treat people with multiple
myeloma who have received at least one prior therapy.
Ixazomib is the first oral proteasome inhibitor and is approved
in combination with lenalidomide and dexamethasone.
Date: Wednesday, June 29, 2016
Time: 2:00 p.m. Eastern Time
Duration: 1 hour
Presenter Information:
Visit Hematology.org/BuyASHSAP6
to pre-order, and receive your copy
and/or online access in June.
• David P. Steensma, MD, Dana-Farber Cancer Institute,
Boston, MA (Moderator)
• Alexandria Schwarsin, MD, U.S. Food and Drug Administration, Silver Spring, MD
• S. Vincent Rajkumar, MD, Mayo Clinic College of Medicine,
Rochester, MN
Register at www.hematology.org/Webinar629.
PAST ASH WEBINARS
Recordings of ASH Webinars are
available at ASH On Demand. Visit
www.ashondemand.org/Webinars or scan the QR code to the
right to access them.
Webinars recently added to
ASH On Demand include:
ASH/FDA Update on von Willebrand Factor
(Recombinant): The approval of von Willebrand factor
(recombinant) to treat adults 18 years of age or older who have
von Willebrand disease (vWD). This is the first FDA-approved
recombinant von Willebrand factor for the on-demand treatment
and control of bleeding episodes in adults with vWD.
The 2016 Clinical Research Training Institute final